Harmine, an efficient cancer cell photosensitizer (PS), emits intense violet color when it is incorporated in well established self assembly based drug carrier formed by cationic surfactants of identical positive charge of head group but varying chain length, namely, dodecyltrimethylammonium bromide (DTAB), tetradecyltrimethylammonium bromide (TTAB) and cetyltrimethylammonium bromide (CTAB). Micelle entrapped drug emits in the UV region when it interacts with non-toxic β-cyclodextrin (β-CD). Inspired by these unique fluorescence/structural switching properties of the anticancer drug, in the present work we have monitored the interplay of the drug between micelles and non-toxic β-CDs. We have observed that the model membranes formed by micelles differing in their hydrophobic chain length interact with the drug differently. Variation in the surfactant chain length plays an important role for structural switching i.e. in choosing a particular structural form of the drug that will be finally presented to their targets. The present study shows that in case of necessity, the bound drug molecule can be removed from its binding site in a controlled manner by the use of non-toxic β-CD and it is exploited to serve a significant purpose for the removal of excess/unused adsorbed drugs from the model cell membranes. We believe this kind of β-CD driven translocation of drugs monitored by fluorescence switching may find possible applications in controlled release of the drug inside cells.

Harmine是一种有效的癌细胞光敏剂（PS），当将其掺入由完全相同的头基带正电荷但链长不同的阳离子表面活性剂（即十二烷基三甲基溴化铵（DTAB））形成的成熟的基于自组装的药物载体中时，发出强烈的紫罗兰色。 ，十四烷基三甲基溴化铵（TTAB）和十六烷基三甲基溴化铵（CTAB）。当胶束包裹的胶束与无毒的β-环糊精（β-CD）相互作用时，它会在UV区域发光。受抗癌药独特的荧光/结构转换特性启发，在本工作中，我们已经监测了胶束与无毒β-CD之间的相互作用。我们已经观察到由疏水链长度不同的胶束形成的模型膜与药物的相互作用不同。表面活性剂链长的变化对于结构转换起着重要作用，即在选择最终呈现给其靶标的药物的特定结构形式时。本研究表明，在必要的情况下，可以通过使用无毒的β-CD以受控的方式将结合的药物分子从其结合位点中除去，并且该药物被用于去除多余的/模型细胞膜上未使用的吸附药物。我们相信，这种通过荧光转换监测的β-CD驱动的药物转运可能会在药物在细胞内部的受控释放中找到可能的应用。本研究表明，在必要的情况下，可以通过使用无毒的β-CD以受控的方式将结合的药物分子从其结合位点中除去，并且该药物被用于去除多余的/模型细胞膜上未使用的吸附药物。我们相信，这种通过荧光转换监测的β-CD驱动的药物转运可能会在药物在细胞内部的受控释放中找到可能的应用。本研究表明，在必要的情况下，可以通过使用无毒的β-CD以受控的方式将结合的药物分子从其结合位点中除去，并且该药物被用于去除多余的/模型细胞膜上未使用的吸附药物。我们相信，这种通过荧光转换监测的β-CD驱动的药物转运可能会在药物在细胞内部的受控释放中找到可能的应用。